Additional Information

The OZEMPIC® (Semaglutide) injection 1mg pen is a once-weekly GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; its mechanism of action leverages the native GLP-1 function to stimulate insulin secretion and suppress glucagon secretion in a glucose-dependent manner, thereby effectively lowering A1C with a low risk of hypoglycemia.